Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Research Article on Live Attenuated Vaccines: Market Dynamics, Major Companies Analysis and Forecast

Author: Sumaiya Khan
by Sumaiya Khan
Posted: Feb 28, 2019
live attenuated

MRFR Reports Provides Prominent Analysis of Global Live Attenuated Vaccines Market report by geographical overview, major products, applications, and key players.

Global Live Attenuated Vaccines Market – Overview

Global live attenuated vaccines market was about is expected to reach USD 45.2 billion by 2023 at a CAGR of 10.7% during forecast period 2017 to 2023. Increasing prevalence of disease, increasing awareness regarding immunization and vaccination drive the growth of this market. Joint effort of government agencies and Non-Government Organization (NGO) to curb the spreads of diseases also contribute to the growth of this market.

Vaccines created by reducing the virulence of pathogens are known as Live Attenuated Vaccines (LAV). These pathogens are weakened under laboratory conditions. The vaccine triggers a potent immune response against infectious diseases.

Request Sample copy at

They initiate memory cell production in order to respond to the pathogen that previously invaded the body. Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of this market. Improving healthcare infrastructure, increasing demand for LAV, and emphasis on prevention of diseases also drives this market.

Availability of funds from government agencies, vaccination programs carried out across the region and technological advancement in vaccine production drive this market in America. World Health Organization (WHO) launched Global Vaccine Action Plan in May 2012 with a motive of strengthening immunization programs and reduce the occurrence of infectious diseases. It was a product of Decade of Vaccines Collaboration (DoV) and consisted of 194 member states. Guidelines were published by UNICEF and WHO to develop a plan for immunization. In 1963 the government introduced measles vaccine, which resulted into a significant decline in mortality rate caused by measles. States in the U.S have made vaccination mandatory before admitting a child to school. Schools are also taking a major initiative in vaccination of children.

Competitive Analysis:

live attenuated vaccines is characterised by the presence of several well-established and small players, the global market of live attenuated vaccines appears to be highly competitive and fragmented. Global players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. These players possess state of art manufacturing facilities and strong sales and distribution network which have helped them to gain leadership position in the market.

For instance, companies like in September 2017, Merck has launched INNOVAX-ND-IBD, the first live vaccine made with biotechnology that protects against three highly infectious diseases in poultry Infectious Bursal Disease (IBD), Newcastle Disease (ND), and Marek’s disease (MD). When given to chickens either in ovo or subcutaneously in the hatchery, it provides life-long protection for ND, IBD and MD simultaneously.

Moreover, October 2017, Company named MedImmune a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer has entered into a licensing agreement under which GamaMabs will use MedImmune’s proprietary pyrrolobenzodiazepine (PBD) toxin and linker technology to research and produce an antibody-drug conjugate (ADC) as a potential cancer therapy.

Top Players:

GlaxoSmithKline, plc. (U.K.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), MedImmune, LLC (U.S.), Sanofi (France), and Serum Institute of India Pvt. Ltd. (India).

Browse Complete 110 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at


Global live attenuated vaccines market is segmented on the basis of type, which includes bacterial and viral vaccines. Bacterial vaccines includes BCG vaccine, and viral vaccine include oral polio vaccine (OPV), measles, rotavirus, and yellow fewer & other viral vaccines. On the basis of vaccine development, the market is segmented into tissue culture, embryonated eggs, live animals, and on the basis of end users, it is sub-segmented into hospitals, clinics, diagnostic centers, research institute & others.

TOC of Live Attenuated Vaccines Market Research Report- Forecast To 2023:

1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology


To know more Updates Related Report Visit at

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.


Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312


About the Author

Healthcare is an ever-evolving domain, that’s why we explicitly ensure to keep a close watch at the market while giving you fresh new insights of the market every now and then. Our reports pertain to preventive, diagnostic, surgical devices and many

Rate this Article
Author: Sumaiya Khan

Sumaiya Khan

Member since: Feb 25, 2019
Published articles: 117

Related Articles